ClinicalTrials.gg
CompletedNCT05538312Updated Sep 23, 2024Results posted

A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy Adults

A Phase 1 interventional study of vepdegestrant and Itraconazole in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-23.

Sponsored by Pfizer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to understand if a strong CYP3A4 inhibitor (itraconazole) affects how ARV-471 is processed and eliminated in healthy adults.

All participants in this study will receive one dose of ARV-471 alone by mouth in Period 1. In Period 2, everyone will receive itraconazole by mouth once a day for multiple days. Participants will also receive one dose of ARV-471 by mouth. The levels of ARV-471 in Period 1 will be compared to the levels of ARV-471 in Period 2 to determine if the CYP3A4 inhibitor affects how ARV-471 is processed differently in healthy adults.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female participants of non- who are overtly healthy as determined by medical evaluation including medical history, physical exam, laboratory tests, vital signs and standard 12-lead ECGs and are between the ages of 18 and 65 years, inclusive at the time of signing the document.
  • of 17.5 to 30.5 kg/meters squared; and a body weight >50 kg.
  • Evidence of a personally signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study.
  • Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.

Exclusion criteria

Exclusion Criteria

  • Evidence or history of hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Pregnant female participants, breastfeeding female participants, female participants of .
  • Male participants with partners currently pregnant; male participants who are unwilling or unable to use a highly effective method of .
  • Use of prescription or non-prescription medications, including vitamins, herbal and dietary supplements, grapefruit/grapefruit containing products, and Seville orange/Seville orange containing products within 7 days prior to the first dose of study intervention with the exception of:

Moderate/potent inducers which are prohibited within 14 days plus 5 half-lives (whichever is longer) prior to the first dose of study intervention.

Moderate/potent CYP3A inhibitors which are prohibited within 14 days or 5 half lives (whichever is longer) prior to the first dose of study intervention.

  • Previous administration with an product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
  • A positive urine drug test or alcohol breath test at discretion of investigator.
  • Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest.
  • Standard 12 lead that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results.
  • or alanine aminotransferase level ≥ 1.0 × .
  • Total level >1.0 × upper limit of normal; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ upper limit of normal.
  • History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening.
  • History of use of tobacco or nicotine-containing products in excess of the equivalent of 5 cigarettes/day or 2 chews of tobacco/day.
  • Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
  • Known or previous adverse events associated with azole antifungals or any of the formulation components of ARV-471.
  • History of sensitivity to heparin or heparin induced thrombocytopenia.
  • Estimated \<60 mL/min/1.73m2.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    vepdegestrant with and without itraconazole

    vepdegestrant administered as a single dose in Period 1 and Period 2. Itraconazole administered once a day for 11 days in Period 2.

    Drug: vepdegestrant · Drug: Itraconazole

Interventions

  • Participants will receive a single dose of vepdegestrant by mouth in Period 1 and Period 2, with a washout period of at least 10 days between doses of vepdegestrant

    Also known as: ARV-471, PF-07850327

  • Participants will receive itraconazole by mouth once a day for 11 days in Period 2.

    Also known as: Sporanox

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf) of ARV-471

    AUCinf was defined as area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUCinf) of ARV-471. AUCinf was calculated by AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.

    Time frame: Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose

  2. Maximum Observed Plasma Concentration (Cmax) of ARV-471

    Cmax was defined as maximum plasma concentration. Cmax of ARV-471 was observed directly from data.

    Time frame: Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose

  3. Area Under the Plasma Concentration-Time Profile From Time 0 to 120 Hours (AUC120) of ARV-473

    ARV-473 was the epimer of ARV-471. AUC120 was defined as area under the plasma concentrationtime profile from time zero to 120 hours. AUC120 was calculate by Linear/Log trapezoidal method.

    Time frame: Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose

  4. Cmax of ARV-473

    ARV-473 was the epimer of ARV-471. Cmax was defined as maximum plasma concentration. Cmax of ARV-473 was observed directly from data.

    Time frame: Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose

Secondary outcomes

  1. Area Under the Plasma Concentration Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of ARV-471

    AUClast was defined as area under the plasma concentrationtime profile from time zero to the time of the last quantifiable concentration (Clast). AUClast was calculated by Linear/Log trapezoidal method.

    Time frame: Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose

  2. AUC120 of ARV-471

    AUC120 was defined as area under the plasma concentrationtime profile from time zero to 120 hours. AUC120 was calculate by Linear/Log trapezoidal method.

    Time frame: Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose

  3. Time for Cmax (Tmax) of ARV-471

    Time for Cmax of ARV-471 was observed directly from data as time of first occurrence.

    Time frame: Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose

  4. Terminal Half-Life (t1/2) of ARV-471

    Terminal half-life (t1/2) was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose

  5. Apparent Clearance After Oral Dose (CL/F) of ARV-471

    CL/F was defined as apparent oral clearance and calculated by dose/AUCinf. AUCinf was defined as area under the plasma concentration-time curve from time 0 extrapolated to infinite time.

    Time frame: Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose

  6. Apparent Volume of Distribution After Oral Dose (Vz/F) of ARV-471

    Vz/F was defined as apparent volume of distribution calculated by dose/(AUCinf \* kel). AUCinf was defined as area under the plasma concentration-time curve from time 0 extrapolated to infinite time and kel was defined as the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

    Time frame: Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose

  7. AUClast of ARV-473

    ARV-473 was the epimer of ARV-471. AUClast was defined as area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (Clast). AUClast was calculated by Linear/Log trapezoidal method.

    Time frame: Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose

  8. Tmax of ARV-473

    ARV-473 was the epimer of ARV-471. Time for Cmax of ARV-473 was observed directly from data as time of first occurrence.

    Time frame: Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose

  9. Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship with the study intervention. SAE is defined as one of the following: is fatal or life threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; is medically significant; requires inpatient hospitalization or prolongation of existing hospitalization. Treatment-emergent AE is defined as an AE with onset date occurring during the on-treatment period. AEs include all SAEs and non-SAEs.

    Time frame: From the first dose (Day 1) up to 35 days after the last dose of study intervention (up to 52 days)

  10. Number of Participants With Clinical Laboratory Abnormalities

    Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid, cystatinC); electrolytes (sodium, potassium, chloride, calcium, bicarbonate); clinical chemistry (glucose); urinalysis (dipstick \[decimal logarithm of reciprocal of hydrogen ion activity {pH} of urine, glucose, protein, blood, ketones, nitrites, leukoesterase, urobilinogen, bilirubin\], microscopy. Abnormality was determined at the investigator's discretion.

    Time frame: Baseline (Period 1 Day -1) up to Period 2 Day 12 (19 days)

  11. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Vital signs (blood pressure and pulse rate) were obtained with participant following at least a 5-minute rest in a supine position. Clinical significance of vital signs was determined at the investigator's discretion.

    Time frame: Baseline (Period 1 Day 1) up to Period 2 Day 5 (11 days)

  12. Number of Participants With Electrocardiogram (ECG) Abnormalities

    ECG abnormalities criteria include a) a postdose QTc corrected using Fridericia's formula (QTcF) increased by ≥60 millisecond (ms) from the baseline and the absolute QTcF value \>450 ms; or b) an absolute QTcF value ≥500 ms for any scheduled ECG.

    Time frame: Baseline (Period 1 Day 1) up to Period 2 Day 12 (18 days)

07

Results

Posted Sep 23, 2024
Limitations and caveats
AUCinf for ARV-473 could only be reported for 2 of 12 participants in Period 1 (ARV-471 alone) and 6 of 12 participants in Period 2 (ARV-471 + itraconazole) based on protocol prespecified criteria, therefore was not used as the primary endpoint for ARV-473. Furthermore, AUC120, was selected as the primary endpoint for ARV-473 in lieu of AUClast to account for the difference in sampling intervals between Test Treatment (0-168 hours) and Reference Treatment (0-120 hours).

Participant flow

Period 1 (6 Days)
Participant flow — Period 1 (6 Days)
MilestoneAll Participants
Started12
Completed12
Not completed0
Period 2 (12 Days)
Participant flow — Period 2 (12 Days)
MilestoneAll Participants
Started12
Completed12
Not completed0

Outcome measures

PrimaryArea Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf) of ARV-471

AUCinf was defined as area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUCinf) of ARV-471. AUCinf was calculated by AUClast + (Clast/kel), where Clast was the predicted plasma concentration at the last quantifiable time point from the log-linear regression analysis and kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration time curve.

Time frame:
Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose
Reported as:
Geometric mean · nanogram*hour per milliliter (ng*hr/mL)
Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf) of ARV-471
nanogram*hour per milliliter (ng*hr/mL)Period 1: ARV-471 200 mgPeriod 2: ARV-471 200 mg + Itraconazole 200 mg
Area Under the Plasma Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf) of ARV-47118960 ± 2332020 ± 24
Statistical analysis
  • Period 1: ARV-471 200 mg vs Period 2: ARV-471 200 mg + Itraconazole 200 mg · Ratio (%) of adjusted geometric means: 168.90 · 90% CI 157.66 to 180.94The ratios (and 90% CIs) are expressed as percentages.
PrimaryMaximum Observed Plasma Concentration (Cmax) of ARV-471

Cmax was defined as maximum plasma concentration. Cmax of ARV-471 was observed directly from data.

Time frame:
Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of ARV-471
nanogram per milliliter (ng/mL)Period 1: ARV-471 200 mgPeriod 2: ARV-471 200 mg + Itraconazole 200 mg
Maximum Observed Plasma Concentration (Cmax) of ARV-471517.9 ± 22788.2 ± 19
Statistical analysis
  • Period 1: ARV-471 200 mg vs Period 2: ARV-471 200 mg + Itraconazole 200 mg · Ratio (%) of adjusted geometric means: 152.19 · 90% CI 136.90 to 169.18The ratios (and 90% CIs) are expressed as percentages.
PrimaryArea Under the Plasma Concentration-Time Profile From Time 0 to 120 Hours (AUC120) of ARV-473

ARV-473 was the epimer of ARV-471. AUC120 was defined as area under the plasma concentrationtime profile from time zero to 120 hours. AUC120 was calculate by Linear/Log trapezoidal method.

Time frame:
Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration-Time Profile From Time 0 to 120 Hours (AUC120) of ARV-473
ng*hr/mLPeriod 1: ARV-471 200 mgPeriod 2: ARV-471 200 mg + Itraconazole 200 mg
Area Under the Plasma Concentration-Time Profile From Time 0 to 120 Hours (AUC120) of ARV-4734734 ± 307668 ± 28
Statistical analysis
  • Period 1: ARV-471 200 mg vs Period 2: ARV-471 200 mg + Itraconazole 200 mg · Ratio (%) of adjusted geometric means: 161.99 · 90% CI 148.70 to 176.47The ratios (and 90% CIs) are expressed as percentages.
PrimaryCmax of ARV-473

ARV-473 was the epimer of ARV-471. Cmax was defined as maximum plasma concentration. Cmax of ARV-473 was observed directly from data.

Time frame:
Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose
Reported as:
Geometric mean · ng/mL
Cmax of ARV-473
ng/mLPeriod 1: ARV-471 200 mgPeriod 2: ARV-471 200 mg + Itraconazole 200 mg
Cmax of ARV-47356.37 ± 2686.31 ± 27
Statistical analysis
  • Period 1: ARV-471 200 mg vs Period 2: ARV-471 200 mg + Itraconazole 200 mg · Ratio (%) of adjusted geometric means: 153.13 · 90% CI 138.51 to 169.30The ratios (and 90% CIs) are expressed as percentages.
SecondaryArea Under the Plasma Concentration Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of ARV-471

AUClast was defined as area under the plasma concentrationtime profile from time zero to the time of the last quantifiable concentration (Clast). AUClast was calculated by Linear/Log trapezoidal method.

Time frame:
Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of ARV-471
ng*hr/mLPeriod 1: ARV-471 200 mgPeriod 2: ARV-471 200 mg + Itraconazole 200 mg
Area Under the Plasma Concentration Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of ARV-47116730 ± 2428710 ± 21
Statistical analysis
  • Period 1: ARV-471 200 mg vs Period 2: ARV-471 200 mg + Itraconazole 200 mg · Ratio (%) of adjusted geometric means: 171.63 · 90% CI 159.96 to 184.15The ratios (and 90% CIs) are expressed as percentages.
SecondaryAUC120 of ARV-471

AUC120 was defined as area under the plasma concentrationtime profile from time zero to 120 hours. AUC120 was calculate by Linear/Log trapezoidal method.

Time frame:
Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
AUC120 of ARV-471
ng*hr/mLPeriod 1: ARV-471 200 mgPeriod 2: ARV-471 200 mg + Itraconazole 200 mg
AUC120 of ARV-47116730 ± 2426400 ± 20
Statistical analysis
  • Period 1: ARV-471 200 mg vs Period 2: ARV-471 200 mg + Itraconazole 200 mg · Ratio (%) of adjusted geometric means: 157.80 · 90% CI 146.51 to 169.95The ratios (and 90% CIs) are expressed as percentages.
SecondaryTime for Cmax (Tmax) of ARV-471

Time for Cmax of ARV-471 was observed directly from data as time of first occurrence.

Time frame:
Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose
Reported as:
Median · hour
Time for Cmax (Tmax) of ARV-471
hourPeriod 1: ARV-471 200 mgPeriod 2: ARV-471 200 mg + Itraconazole 200 mg
Time for Cmax (Tmax) of ARV-4716.00 (2.00 to 8.00)6.00 (4.00 to 8.00)
SecondaryTerminal Half-Life (t1/2) of ARV-471

Terminal half-life (t1/2) was calculated by Loge(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose
Reported as:
Mean · hour
Terminal Half-Life (t1/2) of ARV-471
hourPeriod 1: ARV-471 200 mgPeriod 2: ARV-471 200 mg + Itraconazole 200 mg
Terminal Half-Life (t1/2) of ARV-47142.64 ± 4.080061.57 ± 9.1196
SecondaryApparent Clearance After Oral Dose (CL/F) of ARV-471

CL/F was defined as apparent oral clearance and calculated by dose/AUCinf. AUCinf was defined as area under the plasma concentration-time curve from time 0 extrapolated to infinite time.

Time frame:
Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose
Reported as:
Geometric mean · liter per hour (L/hr)
Apparent Clearance After Oral Dose (CL/F) of ARV-471
liter per hour (L/hr)Period 1: ARV-471 200 mgPeriod 2: ARV-471 200 mg + Itraconazole 200 mg
Apparent Clearance After Oral Dose (CL/F) of ARV-47110.54 ± 236.245 ± 24
SecondaryApparent Volume of Distribution After Oral Dose (Vz/F) of ARV-471

Vz/F was defined as apparent volume of distribution calculated by dose/(AUCinf \* kel). AUCinf was defined as area under the plasma concentration-time curve from time 0 extrapolated to infinite time and kel was defined as the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.

Time frame:
Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose
Reported as:
Geometric mean · liter (L)
Apparent Volume of Distribution After Oral Dose (Vz/F) of ARV-471
liter (L)Period 1: ARV-471 200 mgPeriod 2: ARV-471 200 mg + Itraconazole 200 mg
Apparent Volume of Distribution After Oral Dose (Vz/F) of ARV-471645.6 ± 29549.5 ± 20
SecondaryAUClast of ARV-473

ARV-473 was the epimer of ARV-471. AUClast was defined as area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (Clast). AUClast was calculated by Linear/Log trapezoidal method.

Time frame:
Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose
Reported as:
Geometric mean · ng*hr/mL
AUClast of ARV-473
ng*hr/mLPeriod 1: ARV-471 200 mgPeriod 2: ARV-471 200 mg + Itraconazole 200 mg
AUClast of ARV-4734734 ± 309129 ± 31
Statistical analysis
  • Period 1: ARV-471 200 mg vs Period 2: ARV-471 200 mg + Itraconazole 200 mg · Ratio (%) of adjusted geometric means: 192.86 · 90% CI 178.86 to 207.94The ratios (and 90% CIs) are expressed as percentages.
SecondaryTmax of ARV-473

ARV-473 was the epimer of ARV-471. Time for Cmax of ARV-473 was observed directly from data as time of first occurrence.

Time frame:
Period 1 Day 1: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, and 120 hours post-dose; Period 2 Day 5: pre-dose, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, and 168 hours post-dose
Reported as:
Median · hour
Tmax of ARV-473
hourPeriod 1: ARV-471 200 mgPeriod 2: ARV-471 200 mg + Itraconazole 200 mg
Tmax of ARV-47324.0 (24.0 to 48.1)35.9 (12.0 to 47.8)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a participant who received study intervention without regard to possibility of causal relationship with the study intervention. SAE is defined as one of the following: is fatal or life threatening; results in persistent or significant disability/incapacity; constitutes a congenital anomaly/birth defect; is medically significant; requires inpatient hospitalization or prolongation of existing hospitalization. Treatment-emergent AE is defined as an AE with onset date occurring during the on-treatment period. AEs include all SAEs and non-SAEs.

Time frame:
From the first dose (Day 1) up to 35 days after the last dose of study intervention (up to 52 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
ParticipantsARV-471 200 mgItraconazole 200 mgARV-471 200 mg + Itraconazole 200 mg
Treatment-emergent AEs232
Treatment-emergent SAEs000
SecondaryNumber of Participants With Clinical Laboratory Abnormalities

Following parameters were analyzed for laboratory examination: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, eosinophils, monocytes, basophils, lymphocytes); liver function (aspartate aminotransferase, alanine aminotransferase, total bilirubin, alkaline phosphatase, albumin, total protein); renal function (blood urea nitrogen, creatinine, uric acid, cystatinC); electrolytes (sodium, potassium, chloride, calcium, bicarbonate); clinical chemistry (glucose); urinalysis (dipstick \[decimal logarithm of reciprocal of hydrogen ion activity {pH} of urine, glucose, protein, blood, ketones, nitrites, leukoesterase, urobilinogen, bilirubin\], microscopy. Abnormality was determined at the investigator's discretion.

Time frame:
Baseline (Period 1 Day -1) up to Period 2 Day 12 (19 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinical Laboratory Abnormalities
ParticipantsARV-471 200 mgARV-471 200 mg + Itraconazole 200 mg
Number of Participants With Clinical Laboratory Abnormalities41
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Vital Signs

Vital signs (blood pressure and pulse rate) were obtained with participant following at least a 5-minute rest in a supine position. Clinical significance of vital signs was determined at the investigator's discretion.

Time frame:
Baseline (Period 1 Day 1) up to Period 2 Day 5 (11 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
ParticipantsARV-471 200 mgARV-471 200 mg + Itraconazole 200 mg
Number of Participants With Clinically Significant Change From Baseline in Vital Signs00
SecondaryNumber of Participants With Electrocardiogram (ECG) Abnormalities

ECG abnormalities criteria include a) a postdose QTc corrected using Fridericia's formula (QTcF) increased by ≥60 millisecond (ms) from the baseline and the absolute QTcF value \>450 ms; or b) an absolute QTcF value ≥500 ms for any scheduled ECG.

Time frame:
Baseline (Period 1 Day 1) up to Period 2 Day 12 (18 days)
Reported as:
Count of participants · Participants
Number of Participants With Electrocardiogram (ECG) Abnormalities
ParticipantsARV-471 200 mgARV-471 200 mg + Itraconazole 200 mg
Number of Participants With Electrocardiogram (ECG) Abnormalities00

Adverse events

Collected over From the first dose (Day 1) up to 35 days after the last dose of study intervention (up to 52 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ARV-471 200 mg0/12 (0%)0/12 (0%)2/12 (16.7%)
Itraconazole 200 mg0/12 (0%)0/12 (0%)3/12 (25%)
ARV-471 200 mg + Itraconazole 200 mg0/12 (0%)0/12 (0%)2/12 (16.7%)
Most frequent other events
Most frequent other events
EventARV-471 200 mgItraconazole 200 mgARV-471 200 mg + Itraconazole 200 mg
Abdominal painGastrointestinal disorders1/121/120/12
DiarrhoeaGastrointestinal disorders1/121/121/12
Gingival discomfortGastrointestinal disorders0/121/120/12
FatigueGeneral disorders0/120/121/12
Back painMusculoskeletal and connective tissue disorders1/120/120/12
SomnolenceNervous system disorders0/120/121/12
Nasal congestionRespiratory, thoracic and mediastinal disorders0/121/120/12

Baseline characteristics

Baseline participants included all participants enrolled and who took at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(Years)All Participants
Mean41.33 ± 11.52
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female1
Male11
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino0
Not Hispanic or Latino12
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American3
White8
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Pfizer Clinical Research Unit - Brussels
    Brussels, Bruxelles-capitale, Région DE B-1070, Belgium
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Apr 2023, 2 months.

Results were first posted in Sep 2024, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2022
First posted
Sep 13, 2022
StartActual
Feb 23, 2023
Primary completionActual
Apr 24, 2023
CompletionActual
May 22, 2023
Results first posted
Sep 23, 2024
Last update
Sep 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05538312
Lead sponsor
Pfizer
Collaborators
Arvinas Estrogen Receptor, Inc.
Responsible party
Sponsor
First posted
Sep 13, 2022
Start date
Feb 23, 2023
Primary completion
Apr 24, 2023
Completion
May 22, 2023
Results posted
Sep 23, 2024
Last update
Sep 23, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vepdegestrant · Itraconazole

Start the discussion